Lipocine (NASDAQ:LPCN) Director John Higuchi Acquires 15,970 Shares of Company Stock

Lipocine Inc. (NASDAQ:LPCN) Director John Higuchi bought 15,970 shares of the firm’s stock in a transaction dated Wednesday, September 30th. The shares were bought at an average price of $2.23 per share, with a total value of $35,613.10. Following the completion of the transaction, the director directly owned 241,365 shares in the company, valued at approximately $538,243.95. This trade represents a 7.09% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Lipocine Trading Down 5.9%

Shares of NASDAQ:LPCN traded down $0.13 during mid-day trading on Thursday, reaching $2.07. The stock had a trading volume of 71,208 shares, compared to its average volume of 32,859. The firm has a 50 day simple moving average of $2.17 and a two-hundred day simple moving average of $2.73. Lipocine Inc. has a twelve month low of $1.81 and a twelve month high of $12.37. The firm has a market cap of $17.06 million, a PE ratio of -1.16 and a beta of 0.40.

Lipocine (NASDAQ:LPCN) last issued its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.21 million. Lipocine had a negative net margin of 755.39% and a negative return on equity of 64.75%. On average, equities analysts anticipate that Lipocine Inc. will post -1.54 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LPCN has been the topic of several research analyst reports. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price objective on shares of Lipocine in a research note on Monday, September 21st. Weiss Ratings raised Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 24th. Cantor Fitzgerald restated an “overweight” rating on shares of Lipocine in a report on Tuesday, September 22nd. Finally, Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a research report on Saturday, July 18th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $4.00.

Institutional Investors Weigh In On Lipocine

Several large investors have recently made changes to their positions in the stock. Eversept Partners LP bought a new stake in Lipocine in the 1st quarter valued at $2,357,000. Seven Fleet Capital Management LP bought a new position in Lipocine during the 1st quarter worth about $998,000. Dimensional Fund Advisors LP increased its holdings in Lipocine by 57.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock worth $153,000 after purchasing an additional 6,982 shares in the last quarter. Stempoint Capital LP acquired a new stake in shares of Lipocine in the 1st quarter valued at about $1,282,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Lipocine in the 1st quarter valued at about $185,000. Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.

Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.